Tag: approved

  • Released Comey Memos Reveal Obama Admin's Endorsement Of Russian Hoax

    Released Comey Memos Reveal Obama Admin's Endorsement Of Russian Hoax

    Authored by Luis Cornelio via Headline USA,

    Newly unclassified memos from disgraced former FBI Director James Comey confirmed that the Obama administration not only welcomed the Russia meddling hoax but also discussed potential post-election actions.

    Journalist Catherine Herridge first shared the October 2016 memos on X on Friday after FBI Director Kash Patel approved their declassification.

    In one memo, Comey asked, “What is the goal? Informing US people? Disrupting Russians.”

    Elsewhere, he contemplated potential steps after President Donald Trump’s election in 2016.

    “What are the circumstances in which we can imagine taking any action after the election,” Comey wrote.

    “I can’t picture it so why threaten any.”

    One note, titled “My Thoughts,” referenced the late Sen. Dianne Feinstein and former Rep. (now Sen.) Adam Schiff, both California Democrats, as putting the FBI “in odd spot.”

    The context behind this last note is unclear.

    On another page, Comey used the acronym “COS,” likely referring to a chief of staff.

    He also entertained the Russia meddling theory.

    “Russians have a view on who should win,” he wrote, adding:

    “SR (Susan Rice/National Security Adviser) •Need IC (intelligence Community) to do their best lay down of what we could say publicly.”

    The memos suggest the outgoing Obama administration embraced the idea that Russia wanted Trump to win the election—a theory that later evolved into claims that Trump colluded with Russia.

    No evidence has ever been produced to substantiate this claim.

    *  *  *

    Astaxanthin is our top-selling supplement. It’s an extremely potent antioxidant and anti-inflammatory. Read about it here, and buy some from us here. Up to 20% off if you get 3 bottles & subscribe. Thank you for your support. 

    Colostrum is our second-best selling supplement. Good for your gut, immune system, recovery, and anti-aging. If you aren’t colostrum-pilled, you need to get researching

    Loading recommendations…

  • Costco Keeps the Abortion Pill Out of Its Pharmacy Shelves—Low Demand Says the Store

    *

  • Costco Wholesale made the call on Monday, August 14th, that it won’t stock the abortion medication mifepristone at its U.S. pharmacies. The decision comes in light of what the retailer calls “a surprisingly small number of customers looking for it.”

    What This Means for Shoppers

    • Pharmacy aisles remain clear of the pill that’s widely available in other states.
    • Those seeking mifepristone will still have to rely on other pharmacies or online suppliers.
    • For Costco members who simply browse for everyday items, the absence is unlikely to cause a stir.

    Costco’s Bottom Line

    “We want to ensure we’re meeting what our customers actually want.” The company added that the product’s demand in its market is lower than expected, making it a non‑profitful addition to the store’s inventory. Those interested in the drug are encouraged to look elsewhere.

    Why This Might Surprise You
    1. Costco stocks a wide array of hard‑to‑find items, from bulk pantry staples to seasonal gear.
    2. Pharmacy tags typically include well‑known prescription medicines; mifepristone is an exception.
    3. The supply chain and the legal framework for abortion drugs differ from other categories.

    Bottom line: Costco’s pharmacy shelves will stay drug‑free when it comes to mifepristone, though it’s still on the radar for health professionals and other retailers.

    Mifepristone and Costco: A Whimsical Take on a Serious Topic

    Picture this: a patient in a cozy Carbondale clinic, ready to take Mifepristone—the first pill in a medical abortion. The drug, first cleared by the FDA in 2000, works by blocking the hormone progesterone that keeps pregnancies alive. According to the FDA, when used correctly, it’s supposed to be safe.

    Costco’s Stance… And Why It’s Stirring Talk

    • Costco’s Keep‑It‑Simple Policy: The retailer is at a loss for a mifepristone drug—most folks get it directly from their doctors, so Costco feels it doesn’t have a market for it.
    • Audience Reactions:
      • Faith‑based groups & investors (like Inspire Investing and the Alliance Defending Freedom) have been vocal—some applaud Costco for not carrying the pill, others call it a significant win.
      • Students for Life America (SFLA) gushed that “It’s a stunning win for life,” urging more companies to mirror Costco’s decision.
    • Legal Counsel’s Standpoint:
      • Michael Ross from the ADF pitched a backup argument: “Retailers keep their doors open to sell everyday stuff. They have nothing to gain by branching into abortion meds.”

    Health Concerns Spark A Review

    In May, Health Secretary Robert F. Kennedy Jr. told the FDA to take a closer look at mifepristone after data surfaced showing that nearly 11 % of users faced serious side‑effects—sepsis and hemorrhage—some might say a red flag. The figure beats the under‑0.5 % rate from early trials noted in the drug’s label.

    “New data is alarming,” Kennedy said, pushing for a label change that reflects the truth.

    Investors Get Involved

    • New York City Comptroller Brad Lander wrote to Costco, warning that failing to stock the drug could upset investors. He noted the city’s retirement system holds $443.9 million in Costco stocks.
    • Other advisors and corporate consultants wrote letters urging Costco not to sell mifepristone, gathering support from thousands of investors and customers.

    Wrap‑Up: The Broader Picture

    Whether you’re a medical professional, a consumer, or a corporate stakeholder, the mifepristone conversation reveals a jumble of medical uncertainty, political pressure, and corporate responsibility. Costco’s decision—whether it was spontaneous or pressure‑driven—has sparked a debate that goes beyond the aisles of discount warehouses.

    One thing stands clear: words and actions from big retailers can resound far beyond their shelves—sometimes even influencing the health outcomes of people just outside their storefronts.

  • Anthropic endorses California's AI safety bill, SB 53

    Anthropic endorses California's AI safety bill, SB 53

    On Monday, Anthropic announced an official endorsement of SB 53, a California bill from state senator Scott Wiener that would impose first-in-the-nation transparency requirements on the world’s largest AI model developers. Anthropic’s endorsement marks a rare and major win for SB 53, at a time when major tech groups like the Consumer Technology Association (CTA) and Chamber for Progress are lobbying against the bill.

    “While we believe that frontier AI safety is best addressed at the federal level instead of a patchwork of state regulations, powerful AI advancements won’t wait for consensus in Washington,” said Anthropic in a blog post. “The question isn’t whether we need AI governance — it’s whether we’ll develop it thoughtfully today or reactively tomorrow. SB 53 offers a solid path toward the former.”

    If passed, SB 53 would require frontier AI model developers like OpenAI, Anthropic, Google, and xAI to develop safety frameworks, as well as release public safety and security reports before deploying powerful AI models. The bill would also establish whistleblower protections to employees who come forward with safety concerns.

    Senator Wiener’s bill specifically focuses on limiting AI models from contributing to “catastrophic risks,” which the bill defines as the death of at least 50 people or more than a billion dollars in damages. SB 53 focuses on the extreme side of AI risk — limiting AI models from being used to provide expert-level assistance in the creation of biological weapons or being used in cyberattacks — rather than more near-term concerns like AI deepfakes or sycophancy.

    California’s Senate approved a prior version of SB 53 but still needs to hold a final vote on the bill before it can advance to the governor’s desk. Governor Gavin Newsom has stayed silent on the bill so far, although he vetoed Senator Weiner’s last AI safety bill, SB 1047.

    Bills regulating frontier AI model developers have faced significant pushback from both Silicon Valley and the Trump administration, which both argue that such efforts could limit America’s innovation in the race against China. Investors like Andreessen Horowitz and Y Combinator led some of the pushback against SB 1047, and in recent months, the Trump administration has repeatedly threatened to block states from passing AI regulation altogether.

    One of the most common arguments against AI safety bills are that states should leave the matter up to federal governments. Andreessen Horowitz’s head of AI policy, Matt Perault, and chief legal officer, Jai Ramaswamy, published a blog post last week arguing that many of today’s state AI bills risk violating the Constitution’s Commerce Clause — which limits state governments from passing laws that go beyond their borders and impair interstate commerce.

    Techcrunch event

    Join 10k+ tech and VC leaders for growth and connections at Disrupt 2025

    Netflix, Box, a16z, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just some of the 250+ heavy hitters leading 200+ sessions designed to deliver the insights that fuel startup growth and sharpen your edge. Don’t miss the 20th anniversary of TechCrunch, and a chance to learn from the top voices in tech. Grab your ticket before Sept 26 to save up to $668.

    Join 10k+ tech and VC leaders for growth and connections at Disrupt 2025

    Netflix, Box, a16z, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just some of the 250+ heavy hitters leading 200+ sessions designed to deliver the insights that fuel startup growth and sharpen your edge. Don’t miss the 20th anniversary of TechCrunch, and a chance to learn from the top voices in tech. Grab your ticket before Sept 26 to save up to $668.

    San Francisco
    |
    October 27-29, 2025

    REGISTER NOW

    However, Anthropic co-founder Jack Clark argues in a post on X that the tech industry will build powerful AI systems in the coming years and can’t wait for the federal government to act.

    “We have long said we would prefer a federal standard,” said Clark. “But in the absence of that this creates a solid blueprint for AI governance that cannot be ignored.”

    OpenAI’s chief global affairs officer, Chris Lehane, sent a letter to Governor Newsom in August arguing that he should not pass any AI regulation that would push startups out of California — although the letter did not mention SB 53 by name.

    OpenAI’s former head of policy research, Miles Brundage, said in a post on X that Lehane’s letter was “filled with misleading garbage about SB 53 and AI policy generally.” Notably, SB 53 aims to solely regulate the world’s largest AI companies — particularly ones that generated a gross revenue of more than $500 million.

    Despite the criticism, policy experts say SB 53 is a more modest approach than previous AI safety bills. Dean Ball, a senior fellow at the Foundation for American Innovation and former White House AI policy adviser, said in an August blog post that he believes SB 53 has a good chance now of becoming law. Ball, who criticized SB 1047, said SB 53’s drafters have “shown respect for technical reality,” as well as a “measure of legislative restraint.”

    Senator Wiener previously said that SB 53 was heavily influenced by an expert policy panel Governor Newsom convened — co-led by leading Stanford researcher and co-founder of World Labs, Fei-Fei Li — to advise California on how to regulate AI.

    Most AI labs already have some version of the internal safety policy that SB 53 requires. OpenAI, Google DeepMind, and Anthropic regularly publish safety reports for their models. However, these companies are not bound by anyone but themselves, so sometimes they fall behind their self-imposed safety commitments. SB 53 aims to set these requirements as state law, with financial repercussions if an AI lab fails to comply.

    Earlier in September, California lawmakers amended SB 53 to remove a section of the bill that would have required AI model developers to be audited by third parties. Tech companies have previously fought these types of third-party audits in other AI policy battles, arguing that they’re overly burdensome.